Overview

A Study to Evaluate the Dose Levels, Safety, and Drug Levels of Single KarXT Intramuscular Injection in Participants With Schizophrenia

Status:
RECRUITING

Trial end date:
2027-10-15

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the dose levels, safety, and drug levels of KarXT intramuscular injection in participants with Schizophrenia

Phase:

PHASE1

Details

Lead Sponsor:

Bristol-Myers Squibb